You are here

Flowable keratin biomaterials for improving infection control and wound healing, Phase 2.

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-12-C-0004
Agency Tracking Number: A2-5197
Amount: $751,604.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: A11-108
Solicitation Number: 2011.2
Timeline
Solicitation Year: 2011
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-06-21
Award End Date (Contract End Date): 2013-11-21
Small Business Information
Richard Dean Research Building, Suite 168 391 Tech
Winston-Salem, NC 27101-3074
United States
DUNS: 000000000
HUBZone Owned: Yes
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Seth Tomblyn
 Principal Scientist
 (336) 725-0621
 seth.tomblyn@KeraNetics.com
Business Contact
 Kim Westmoreland
Title: Managing Director
Phone: (336) 725-0621
Email: kim.westmoreland@KeraNetics.com
Research Institution
 Stub
Abstract

Improvements in body armor, availability of equipment, and decreased patient transport times have dramatically improved Soldiers survival of combat injuries. Data suggests that future conflicts will require more aggressive wound management at the point of injury to deal with more complex wounds, particularly with respect to infection control. There is a significant need to develop and translate platform technologies that can address these injuries while providing infection control. This proposal seeks to build on Phase I work using a flowable keratin based carrier system for slow-release of antibiotics. Data from our Phase I project demonstrated that flowable keratin biomaterials loaded with antibiotics (KeraStat ICG) supported keratinocyte and fibroblast proliferation while preventing colony formation of Gram-positive, Gram-negative and anaerobic bacteria. This Phase II project seeks to expand these findings into in vivo models of infected excisional and burn wounds, comparing our KeraStat ICG formulation to the standard of care for these injuries. Additionally, we will conduct safety and stability testing necessary for filing this combination product with the FDA.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government